2024
Optimization criteria for ordering myeloid neoplasm next‐generation sequencing
Gisriel S, Howe J, Tormey C, Torres R, Hager K, Rinder H, Siddon A. Optimization criteria for ordering myeloid neoplasm next‐generation sequencing. EJHaem 2024 DOI: 10.1002/jha2.1036.Peer-Reviewed Original ResearchNext-generation sequencingNext-generation sequencing testMyeloid neoplasmsDiagnosis of chronic myeloid leukemiaAltering treatment plansEnd-of-inductionFluorescence in situ hybridizationRecurrence post-transplantChronic myeloid leukemiaSuspicion of progressionPathogenic mutationsClinical suspicionMutation statusMN diagnosisMyeloid leukemiaPost-transplantRisk stratificationWorsening diseaseTreatment planningCancellation criteriaSuspicionDiagnosisSequenceCenters for MedicareB testCurrent state and potential applications of neonatal Fc receptor (FcRn) inhibitors in hematologic conditions
Jacobs J, Booth G, Raza S, Clark L, Fasano R, Gavriilaki E, Abels E, Binns T, Duque M, McQuilten Z, Mingot‐Castellano M, Savani B, Sharma D, Tran M, Tormey C, Moise K, Bloch E, Adkins B. Current state and potential applications of neonatal Fc receptor (FcRn) inhibitors in hematologic conditions. American Journal Of Hematology 2024 PMID: 39324647, DOI: 10.1002/ajh.27487.Peer-Reviewed Original ResearchHematological conditionsFcRn inhibitorsClinical trialsStandardized treatment algorithmClinical trial dataNeonatal Fc receptorIn vivo studiesImmune-mediatedHematological disordersTreatment algorithmTransports IgGAdverse eventsImmunomodulatory/immunosuppressive therapiesIgG levelsPatient populationProtective IgGFc receptorsTherapeutic strategiesMucosal surfacesRheumatologic conditionsIgG antibodiesImmunoglobulin isotypesTrial dataIgGFcRnThe effect of plerixafor on autologous stem cell mobilization, cell viability, and apheresis challenges
Puzo C, Li P, Tormey C, Siddon A. The effect of plerixafor on autologous stem cell mobilization, cell viability, and apheresis challenges. Lab Medicine 2024, lmae080. PMID: 39303673, DOI: 10.1093/labmed/lmae080.Peer-Reviewed Original ResearchAutologous stem cell transplantationHematopoietic stem cellsMultiple myelomaG-CSFMobilization failureDiffuse large B-cell lymphomaAutologous stem cell mobilizationLarge B-cell lymphomaGranulocyte colony-stimulating factorAutologous stem cell transplant patientsEfficacy of plerixaforStem cell mobilizationB-cell lymphomaStem cell transplantationEffects of plerixaforRetrospective chart reviewColony-stimulating factorYale-New Haven HospitalCell viabilityMultiple risk factorsHodgkin lymphomaNon-HodgkinMobilization regimenCell transplantationPlerixaforCharacterization of blood bank and transfusion medicine practices for pregnant individuals with fetuses at risk of hemolytic disease in the United States
Jacobs J, Booth G, Moise K, Adkins B, Bakhtary S, Fasano R, Goel R, Hinton H, Laghari S, Stephens L, Tormey C, Crowe E, Bloch E, Abels E. Characterization of blood bank and transfusion medicine practices for pregnant individuals with fetuses at risk of hemolytic disease in the United States. Transfusion 2024, 64: 1870-1880. PMID: 39248602, DOI: 10.1111/trf.18011.Peer-Reviewed Original ResearchRisk of HDFNAntigen testAntibody titersHemolytic diseaseRed blood cellsCell-free fetal DNA testingRisk of hemolytic diseaseCell-free fetal DNAMaternal antibody titersPregnant individualsFetal DNA testingBlood banksTransfusion medicine practiceFetal DNALaboratory testing practicesThird trimesterAntigen statusTransfusion medicine serviceAntigen resultsMedicine serviceFetusesHDFNCritical titerResponse rateDNA testingMixed-field ABO front typing as an early sign of disease recurrence in ABO-matched stem cell transplantation
Yurtsever N, Lee E, Pinatti L, Shah B, Tormey C, Siddon A. Mixed-field ABO front typing as an early sign of disease recurrence in ABO-matched stem cell transplantation. Immunohematology 2024, 40: 89-92. PMID: 39373301, DOI: 10.2478/immunohematology-2024-013.Peer-Reviewed Original ResearchConceptsStem cell transplantationCell transplantationDisease recurrenceMyeloid neoplasmsChimerism testingAllogeneic stem cell transplantationSigns of disease recurrenceIndicator of disease recurrenceDonor-recipient pairsABO antigen expressionGraft statusAntigen expressionFemale patientsPost-transplantationAllograft statusTransplantationABO typeRecurrenceClinical settingEarly signsNeoplasmsChimerismEarly indicatorABOEngraftmentThe seasonal distribution of immune thrombotic thrombocytopenic purpura is influenced by geography: Epidemiologic findings from a multi‐center analysis of 719 disease episodes
Jacobs J, Stanek C, Booth G, Symeonidis A, Shih A, Allen E, Gavriilaki E, Grossman B, Pavenski K, Moorehead A, Peyvandi F, Agosti P, Mancini I, Stephens L, Raval J, Mingot‐Castellano M, Crowe E, Daou L, Pai M, Arnold D, Marques M, Henrie R, Smith T, Sreenivasan G, Siniard R, Wallace L, Yamada C, Duque M, Wu Y, Harrington T, Byrnes D, Bitsani A, Davis A, Robinson D, Eichbaum Q, Villalba C, Juskewitch J, Kaiafa G, Kapsali E, Klapper E, Perez‐Alvarez I, Klein M, Kotsiou N, Lalayanni C, Mandala E, Aldarweesh F, Alkhateb R, Fortuny L, Mellios Z, Papalexandri A, Parsons M, Schlueter A, Tormey C, Wellard C, Wood E, Jia S, Wheeler A, Powers A, Webb C, Yates S, Bouzid R, Coppo P, Bloch E, Adkins B. The seasonal distribution of immune thrombotic thrombocytopenic purpura is influenced by geography: Epidemiologic findings from a multi‐center analysis of 719 disease episodes. American Journal Of Hematology 2024, 99: 2063-2074. PMID: 39136282, DOI: 10.1002/ajh.27458.Peer-Reviewed Original ResearchAddressing platelet insecurity – A national call to action
Gehrie E, Young P, Basavaraju S, Bracey A, P. A, Culler L, Dunbar N, Homer M, Isufi I, Macedo R, Petraszko T, Ramsey G, Tormey C, Kaufman R, Snyder E. Addressing platelet insecurity – A national call to action. Transfusion 2024, 64: 2001-2013. PMID: 39133194, DOI: 10.1111/trf.17987.Peer-Reviewed Original ResearchEfgartigimod for primary immune thrombocytopenia: the ADVANCE IV trial
Jacobs J, Booth G, Stephens L, Tormey C, Adkins B. Efgartigimod for primary immune thrombocytopenia: the ADVANCE IV trial. The Lancet 2024, 404: 433. PMID: 39097393, DOI: 10.1016/s0140-6736(24)01264-9.Peer-Reviewed Original ResearchTherapeutic plasma exchange for hyperviscosity syndrome in IgA multiple myeloma
Yurtsever N, Binns T, Hendrickson J, Tormey C, Lee E. Therapeutic plasma exchange for hyperviscosity syndrome in IgA multiple myeloma. Lab Medicine 2024, lmae054. PMID: 39038224, DOI: 10.1093/labmed/lmae054.Peer-Reviewed Original ResearchA multi‐institutional survey of apheresis services among institutions in the United States
Yurtsever N, Jacobs J, Booth G, Schwartz J, Park Y, Woo J, Lauro D, Torres S, Ward D, Stephens L, Allen E, Tormey C, Adkins B. A multi‐institutional survey of apheresis services among institutions in the United States. Journal Of Clinical Apheresis 2024, 39: e22138. PMID: 38979705, DOI: 10.1002/jca.22138.Peer-Reviewed Original ResearchConceptsTherapeutic plasma exchangeRed blood cell exchangeCell collectionSpectra Optia apheresis systemMulti-institutional surveyHematopoietic progenitor cell collectionProgenitor cell collectionUS academic centersCAR-TPlasma exchangeApheresis therapyGene therapyTransfusion medicine serviceCellular therapyApheresis practiceApheresis systemCell exchangeAcademic medical centerClinical trialsAcademic centersHPC-AApheresisMedical CenterTherapyCoronavirus disease 2019Cost-effectiveness of rapid vs in-house vs send-out ADAMTS13 testing for immune thrombotic thrombocytopenic purpura
Allen C, Ito S, Butt A, Purcell A, Richmond R, Tormey C, Krumholz H, Cuker A, Goshua G. Cost-effectiveness of rapid vs in-house vs send-out ADAMTS13 testing for immune thrombotic thrombocytopenic purpura. Blood Advances 2024, 8: 2279-2289. PMID: 38502197, PMCID: PMC11116991, DOI: 10.1182/bloodadvances.2024012608.Peer-Reviewed Original ResearchImmune thrombotic thrombocytopenic purpuraPLASMIC scoreThrombotic thrombocytopenic purpuraThrombocytopenic purpuraADAMTS13 testingIncremental net monetary benefitPer-patient cost savingsTherapeutic plasma exchangeBase-case analysisMarkov cohort simulationProbabilistic sensitivity analysesAmount of QALYEmpirical therapyADAMTS13 assaysPlasma exchangeEmpirical treatmentCaplacizumabFRET-based assayPrimary outcomePatientsNet monetary benefitCohort simulationCost-effectiveness evaluationPurpuraTesting strategiesFactitious disorder presenting as sickle cell disease: a case report
Jacobs J, Guarente J, Karp J, Grossman B, Ziman A, McGonigle A, Binns T, Gish T, Gorham J, Park Y, Perez-Alvarez I, Burner J, Mei Z, Ward D, Woo J, Booth G, Adkins B, Webb C, Yamada C, Lee G, Abels E, Marques M, Allen E, Fasano R, Crowe E, Tobian A, Tormey C, Bloch E. Factitious disorder presenting as sickle cell disease: a case report. The Lancet Regional Health - Americas 2024, 34: 100761. PMID: 38745885, PMCID: PMC11090869, DOI: 10.1016/j.lana.2024.100761.Peer-Reviewed Original ResearchSevere, Refractory Primary Warm Autoimmune Hemolytic Anemia Requiring 90 Erythrocyte Transfusions.
Namineni N, Waldron C, Tormey C, Goshua G. Severe, Refractory Primary Warm Autoimmune Hemolytic Anemia Requiring 90 Erythrocyte Transfusions. Annals Of Internal Medicine Clinical Cases 2024, 3 PMID: 38725710, PMCID: PMC11081177, DOI: 10.7326/aimcc.2023.1141.Peer-Reviewed Original ResearchWarm autoimmune hemolytic anemiaAutoimmune hemolytic anemiaHemolytic anemiaSevere warm autoimmune hemolytic anemiaMonths of follow-upHealthy 60-year-old manTherapeutic plasma exchangeHospital day 1Erythrocyte transfusionTransfusion-dependentRefractory diseasePlasma exchangeImmune globulinHospital stayFollow-upDay 1AnemiaHospitalRituximabReticulocytopeniaRemissionSplenectomyTransfusionPatientsStayThrombosis risk with haemoglobin C trait and haemoglobin C disease: A systematic review
Jacobs J, Sharma D, Stephens L, Villalba C, Rinder H, Woo J, Wheeler A, Gerberi D, Goel R, Tormey C, Booth G, Bloch E, Adkins B. Thrombosis risk with haemoglobin C trait and haemoglobin C disease: A systematic review. British Journal Of Haematology 2024, 204: 1500-1506. PMID: 38291731, DOI: 10.1111/bjh.19313.Peer-Reviewed Original ResearchRisk of thrombosisHemoglobin C traitHemoglobin C diseaseVenous thromboembolismC diseaseIncreased risk of thrombosisProspective cohort studyFactor to thrombosisAssessment of patientsCohort studySystematic reviewInclusion criteriaPregnant individualsThrombotic riskCase seriesCase reportVTE riskChronic haemolysisSystematic literature reviewArterial thrombosisThrombosis riskHigh blood viscosityIncreased riskThrombosisC trait
2023
Heidenhain variant of Creutzfeldt-Jakob disease masquerading as neuromyelitis optica spectrum disorder: recognizing when apheresis is not the answer
Burke O, Jacobs J, Tormey C, Rinder H, Villalba C, Lee E, Campos J, Abels E, Yurtsever N. Heidenhain variant of Creutzfeldt-Jakob disease masquerading as neuromyelitis optica spectrum disorder: recognizing when apheresis is not the answer. Lab Medicine 2023, 55: 520-523. PMID: 38142129, DOI: 10.1093/labmed/lmad107.Peer-Reviewed Original ResearchNeuromyelitis optica spectrum disorderCreutzfeld-Jakob diseaseOptica spectrum disorderHeidenhain variantBilateral vision lossTherapeutic plasma exchangeReal-time quaking-induced conversionCreutzfeldt-Jakob diseaseImmunosuppressive therapyVisual disturbancesPlasma exchangeNeurocognitive symptomsTreatment modalitiesVision lossHospice careSpectrum disorderRare formPreliminary diagnosisDiseaseDiagnosisDisordersEarly stagesPatientsApheresisTherapyAssessing Recommendations for Determining Fetal Risk in Alloimmunized Pregnancies in the United States: Is It Time to Update a Decades-Old Practice?
Abels E, Adkins B, Cedeno K, Booth G, Allen E, Stephens L, Woo J, Tormey C, Jacobs J. Assessing Recommendations for Determining Fetal Risk in Alloimmunized Pregnancies in the United States: Is It Time to Update a Decades-Old Practice? Transfusion Medicine Reviews 2023, 38: 150810. PMID: 38194730, DOI: 10.1016/j.tmrv.2023.150810.Peer-Reviewed Original ResearchAntigen testingEvidence-based recommendationsFetal risksAlloimmunized pregnanciesPoor outcomeHemolytic diseasePractice guidelinesDecades-old practiceNarrative reviewTransfusion medicineUnnecessary riskRecent evidencePregnancyUnited StatesFetusesRiskCurrent United StatesValuable alternativeTesting algorithmObstetriciansCurrent landscapeDiseaseRecommendationsComprehensive Characterization of Coagulation Parameters in Venous Malformations
Restrepo V, Pine A, Butt A, Chang E, Bar N, Baluha A, Brooks A, Chirico G, Curran J, Dumont A, Obura-Wilkes P, Rinder H, Tormey C, Nassiri N, Lee A, Prozora S. Comprehensive Characterization of Coagulation Parameters in Venous Malformations. Blood 2023, 142: 27. DOI: 10.1182/blood-2023-190609.Peer-Reviewed Original ResearchHigher thrombin-antithrombin complexesNormal D-dimerThrombin-antithrombin complexPlasminogen activator inhibitor-1Localized intravascular coagulopathyInternational normalized ratioD-dimerVenous malformationsCoagulation parametersPartial thromboplastin timeCoagulation testsFactor VIIIVWF activityChart reviewMost patientsHematology clinicProthrombin timeTissue involvementVWF antigenVon Willebrand factor antigenHigher TAT levelsMultiple coagulation parametersBaseline patient characteristicsRetrospective chart reviewCoagulation test results
2022
Alloimmunization following antigen‐negative red blood cell transfusion
Jacobs J, Binns T, Abels E, Iyer K, Villalba C, Verma A, Sostin N, Tormey C. Alloimmunization following antigen‐negative red blood cell transfusion. Transfusion 2022, 63: 430-434. PMID: 36458330, DOI: 10.1111/trf.17208.Peer-Reviewed Case Reports and Technical NotesConceptsTransfusion of RBCsRed blood cell transfusionRed blood cell alloimmunizationPrevious antigen exposureBlood cell transfusionAlloantibody specificitiesCell transfusionRBC transfusionAntigen exposureRBC alloantibodiesAntigenic stimulusDetectable titersAntigenic stimulationMyeloid neoplasmsTransfusionAlloantibodiesAlloimmunizationParticular antigenPrior exposureStimulatory eventsExact mechanismCorresponding antibodiesRBCsExposurePregnancyAssessment of polymicrobial interactions in bacterial isolates from transfused platelet units associated with sepsis
Kerantzas CA, Merwede J, Snyder EL, Hendrickson JE, Tormey CA, Kazmierczak BI, Peaper DR. Assessment of polymicrobial interactions in bacterial isolates from transfused platelet units associated with sepsis. Transfusion 2022, 62: 2458-2463. PMID: 36178430, PMCID: PMC11472026, DOI: 10.1111/trf.17136.Peer-Reviewed Original ResearchConceptsAcinetobacter calcoaceticus-baumannii complexBlood productsS. saprophyticusPlatelet unitsContaminated blood productsCDC investigationsApheresis platelet productsTransfusion reactionsPolymicrobial contaminationPlatelet productsDisease controlBacterial isolatesStudy designStaphylococcus saprophyticusPolymicrobial interactionsCDC casesSaprophyticusFuture studiesPotential interactionsCommon sourceSepsisIsolatesCasesCoaggregationProcuring rare (珍しい)* Japanese red blood cell units for a bleeding patient with anti-K11 requiring a life-saving procedure
Rodriguez J, Tormey C. Procuring rare (珍しい)* Japanese red blood cell units for a bleeding patient with anti-K11 requiring a life-saving procedure. Immunohematology 2022, 38: 96-99. PMID: 36190197, DOI: 10.21307/immunohematology-2022-049.Peer-Reviewed Case Reports and Technical NotesConceptsAmerican Rare Donor ProgramRed blood cell unitsAntigen-positive unitsLife-saving procedurePotential clinical significanceMultiple comorbiditiesKnee amputationExtremity amputationCritical anemiaCase reportAdverse reactionsClinical significanceCell unitsPatient plasmaTransfusion communityGroup OClinical necessityDonor ProgramRBC unitsPatientsAmputationCompatible unitsAnemiaChallenging caseRare event